Infant Bacterial Therapeutics’ (IBT) publishes clinical findings in the British Journal of Gastroenterology on the convincing association of clinical events to the feeding primary endpoint of the ‘Connection Study’
24 janv. 2023 11h43 HE
|
Infant Bacterial Therapeutics AB
The ‘Connection Study’ on the pharmaceutical grade probiotic IBP-9414 has two independent primary endpoints- the incidence of Necrotizing Enterocolitis (NEC) and the time to a strict definition of...
Artikel baserad på Infant Bacterial Therapeutics “Connection Study” publicerad i British Journal of Gastroenterology visar att en dags minskning av tiden till “Sustained Feeding Tolerance (SFT)” korrelerar med klinisk meningsfulla resultat
01 nov. 2022 03h00 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics (IBT) "Connection Study" består av två oberoende primära endpoints, förekomsten av NEC och tiden tills man når SFT. SFT ett sammansatt effektmått definierat som den...
Article based on Infant Bacterial Therapeutics’ (IBT) Connection Study published in the British Journal of Gastroenterology demonstrates that one day shift in Sustained Feeding Tolerance (SFT) correlates to clinically meaningful outcomes.
01 nov. 2022 03h00 HE
|
Infant Bacterial Therapeutics AB
The two independent primary endpoints of the ‘Connection Study’ are the incidence of NEC and the time to SFT. SFT a composite endpoint defined as the first day of tolerating daily enteral feeds of...
Infant Bacterial Therapeutics AB (publ) Delårsrapport 1 januari – 30 juni 2022
25 août 2022 02h00 HE
|
Infant Bacterial Therapeutics AB
VD kommenterar Vårt utvecklingsprojekt IBP-9414 i klinisk fas III fortskrider väl, och vi har sett en ökning av rekryteringstakten. Vi har som jag tidigare nämnt arbetat med ett flertal aktiviteter...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement January 1-June 30, 2022
25 août 2022 02h00 HE
|
Infant Bacterial Therapeutics AB
Message from the CEO Our IBP-9414 clinical phase III development program is progressing well. We have seen an overall acceleration of recruitment rates and, as mentioned previously, have been...
Infant Bacterial Therapeutics AB utser Maria Ekdahl till CFO
30 juin 2022 11h00 HE
|
Infant Bacterial Therapeutics AB
Pressmeddelande 30 juni 2022 Infant Bacterial Therapeutics AB (publ) tillkännagav idag att Maria Ekdahl utsetts till Chief Financial Officer (CFO) och tillträder den 19 september 2022. Hon kommer att...
Infant Bacterial Therapeutics AB appoints Maria Ekdahl as CFO
30 juin 2022 11h00 HE
|
Infant Bacterial Therapeutics AB
Press Release June 30, 2022 Infant Bacterial Therapeutics AB (publ) announced today that Maria Ekdahl has been appointed Chief Financial Officer (CFO) effective September 19, 2022. She will be part...
Årsstämma i Infant Bacterial Therapeutics
04 mai 2022 10h00 HE
|
Infant Bacterial Therapeutics AB
På årsstämman i Infant Bacterial Therapeutics AB (publ) den 4 maj 2022 beslutades bland annat följande: fastställande av resultaträkningen och balansräkningen samt koncernresultaträkningen och...
Annual General Meeting of Infant Bacterial Therapeutics
04 mai 2022 10h00 HE
|
Infant Bacterial Therapeutics AB
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among other things, the following was resolved: to adopt the income statement and balance sheet and the...
Energy Management Corporation Announces New Location
07 avr. 2022 11h00 HE
|
Energy Management Corporation
LAS VEGAS, April 07, 2022 (GLOBE NEWSWIRE) -- Energy Management Corporation (EMC) has announced the opening of a new location in Clark County, Nevada. "I'm excited that we are able to build upon...